IL-5对抗作用逆转了在严重的埃索诺菲尔性喘中对埃索诺菲尔的原始化和激活
Jian Luo1, Wentao Chen1, Wei Liu2
1Respiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Mucosal immunology
|March 17, 2024
概括
干白素-5 (IL-5) 驱动在严重喘中产生和激活埃索诺菲尔. 使用梅波利祖马布向IL-5提供了治疗效益,因为它调节了乙氨基酸细胞的功能,并减少了气道炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 分子生物学分子生物学
背景情况:
- 叶绿素是严重的叶绿素性喘的核心,导致呼吸道炎症和恶化.
- 干白素-5 (IL-5) 是埃索诺菲尔细胞的关键生长因子,影响其原始化和激活,尽管机制尚不清楚.
- 抗IL-5抗体梅波利祖马布在严重喘中显示出显著的临床益处,这表明乙素原始化/激活是关键的治疗点.
研究的目的:
- 利用梅波利祖马布的治疗效果,阐明IL-5在乙氨基酸原始化和激活中的机械作用.
- 调查IL-5如何影响乙氨基基基的功能,并有助于重症乙氨基基基喘中呼吸道重塑.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于分析埃索诺菲尔的反应.
- 这项研究利用了梅波利祖马布 (mepolizumab) 的临床疗效作为了解IL-5通路的工具.
主要成果:
- 证实IL-5是乙素原始化和激活的主要驱动因素.
- IL-5通过PI3K,ERK和p38 MAPK信号通路增强了乙氨基细胞的迁移,生存和激活.
- 此外,IL-5还通过TGF-β通路强化了以奥西诺菲尔为媒介的气道重塑.
结论:
- 这项研究提供了一个详细的机理理解IL-5驱动的乙氨基基原始化在严重的乙氨基性喘.
- 这些发现支持了针对IL-5通路的治疗重要性,以管理严重喘中的乙酸细胞功能和呼吸道重塑.
更多相关视频
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
7.7K
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
22.5K
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
294
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
294
01:19Antiasthma Drugs: Leukotriene Modifiers
297
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
297
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
245
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
245
01:24Antiasthma Drugs: Methylxanthines
228
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
228
01:17Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K